In the last trading session, 1.33 million shares of the Beam Therapeutics Inc (NASDAQ:BEAM) were traded, and its beta was 2.16. Most recently the company’s share price was $17.03, and it changed around $0.2 or 1.19% from the last close, which brings the market valuation of the company to $1.71B. BEAM currently trades at a discount to its 52-week high of $35.25, offering almost -106.99% off that amount. The share price’s 52-week low was $13.52, which indicates that the current value has risen by an impressive 20.61% since then. We note from Beam Therapeutics Inc’s average daily trading volume that its 10-day average is 1.43 million shares, with the 3-month average coming to 2.36 million.
Beam Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.39. If we narrow it down even further, the data shows that 0 out of 17 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 3 recommended BEAM as a Hold, whereas 10 deemed it a Buy, and 0 rated it as Underweight.
Beam Therapeutics Inc (NASDAQ:BEAM) trade information
Instantly BEAM has showed a green trend with a performance of 1.19% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 18.31 on recent trading dayincreased the stock’s daily price by 6.99%. The company’s shares are currently down -31.33% year-to-date, but still down -3.54% over the last five days. On the other hand, Beam Therapeutics Inc (NASDAQ:BEAM) is -12.76% down in the 30-day period. We can see from the shorts that 19.26 million shares have been sold at a short interest cover period of 6.75 day(s).
The consensus price target as assigned by Wall Street analysts is $37, which translates to bulls needing to increase their stock price by 53.97% from its current value. Analyst projections state that BEAM is forecast to be at a low of $25 and a high of $55.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -20.88%. Beam Therapeutics Inc earnings are expected to increase by -1.28% in 2025, but the outlook is negative -1.72% per year for the next five years.
BEAM Dividends
Beam Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-05.
Beam Therapeutics Inc (NASDAQ:BEAM)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.22% of Beam Therapeutics Inc shares, and 97.94% of them are in the hands of institutional investors. The stock currently has a share float of 99.15%. Beam Therapeutics Inc stock is held by 348.0 institutions, with FARALLON CAPITAL MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 9.6135% of the shares, which is about 7.91 million shares worth $185.4 million.
VANGUARD GROUP INC, with 9.598% or 7.9 million shares worth $185.11 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Trust-ARK Innovation ETF and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Apr 30, 2025 . The former held 5.7 shares worth $97.09 million, making up 5.67% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 2.4 shares worth around $40.94 million, which represents about 2.39% of the total shares outstanding.
